Europe's drug industry is going through an efficiency drive to cut costs, raise productivity, and focus on more profitable therapeutic areas. Research chemists and other scientists face the prospect of losing their jobs as staff numbers are reduced. Whole research units are being closed or transferred to new owners that want to economize with fewer employees.